Literature DB >> 8891134

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

D Sanglard1, F Ischer, M Monod, J Bille.   

Abstract

Some Candida albicans isolates from AIDS patients with oropharyngeal candidiasis are becoming resistant to the azole antifungal agent fluconazole after prolonged treatment with this compound. Most of the C. albicans isolates resistant to fluconazole fail to accumulate this antifungal agent, and this has been considered a cause of resistance. This phenomenon was shown to be linked to an increase in the amounts of mRNA of a C. albicans ABC (ATP-binding cassette) transporter gene called CDR1 and of a gene conferring benomyl resistance (BENr), the product of which belongs to the class of major facilitator multidrug efflux transporters (D. Sanglard, K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother. 39:2378-2386, 1995). To analyze the roles of these multidrug transporters in the efflux of azole antifungal agents, we constructed C. albicans mutants with single and double deletion mutations of the corresponding genes. The mutants were tested for their susceptibilities to these antifungal agents. Our results indicated that the delta cdr1 C. albicans mutant was hypersusceptible to the azole derivatives fluconazole, itraconazole, and ketoconazole, thus showing that the ABC transporter Cdr1 can use these compounds as substrates. The delta cdr1 mutant was also hypersusceptible to other antifungal agents (terbinafine and amorolfine) and to different metabolic inhibitors (cycloheximide, brefeldin A, and fluphenazine). The same mutant was slightly more susceptible than the wild type to nocodazole, cerulenin, and crystal violet but not to amphotericin B, nikkomycin Z, flucytosine, or pradimicin. In contrast, the delta ben mutant was rendered more susceptible only to the mutagen 4-nitroquinoline-N-oxide. However, this mutation increased the susceptibilities of the cells to cycloheximide and cerulenin when the mutation was constructed in a delta cdr1 background. The assay used in the present study could be implemented with new antifungal agents and is a powerful tool for assigning these substances as putative substrates of multidrug transporters.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891134      PMCID: PMC163524     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Mode of action of clinically important antifungal drugs.

Authors:  D Kerridge
Journal:  Adv Microb Physiol       Date:  1986       Impact factor: 3.517

2.  Isogenic strain construction and gene mapping in Candida albicans.

Authors:  W A Fonzi; M Y Irwin
Journal:  Genetics       Date:  1993-07       Impact factor: 4.562

3.  Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate.

Authors:  M E Fling; J Kopf; A Tamarkin; J A Gorman; H A Smith; Y Koltin
Journal:  Mol Gen Genet       Date:  1991-06

4.  The role of microfilaments and microtubules in apical growth and dimorphism of Candida albicans.

Authors:  K Yokoyama; H Kaji; K Nishimura; M Miyaji
Journal:  J Gen Microbiol       Date:  1990-06

5.  Sensitivity to nikkomycin Z in Candida albicans: role of peptide permeases.

Authors:  J C Yadan; M Gonneau; P Sarthou; F Le Goffic
Journal:  J Bacteriol       Date:  1984-12       Impact factor: 3.490

6.  Molecular cloning and expression of the Saccharomyces cerevisiae STS1 gene product. A yeast ABC transporter conferring mycotoxin resistance.

Authors:  P H Bissinger; K Kuchler
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

7.  Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance.

Authors:  F S Clark; T Parkinson; C A Hitchcock; N A Gow
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  Studies on the mode of action of hygromycin B, an inhibitor of translocation in eukaryotes.

Authors:  A González; A Jiménez; D Vázquez; J E Davies; D Schindler
Journal:  Biochim Biophys Acta       Date:  1978-12-21

9.  Effect of side-chain structure on inhibition of yeast fatty-acid synthase by cerulenin analogues.

Authors:  N Morisaki; H Funabashi; R Shimazawa; J Furukawa; A Kawaguchi; S Okuda; S Iwasaki
Journal:  Eur J Biochem       Date:  1993-01-15

10.  Brefeldin A reversibly blocks early but not late protein transport steps in the yeast secretory pathway.

Authors:  T R Graham; P A Scott; S D Emr
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more
  151 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Evolution of microbial pathogens.

Authors:  J Morschhäuser; G Köhler; W Ziebuhr; G Blum-Oehler; U Dobrindt; J Hacker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

Review 3.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.

Authors:  M D De Backer; T Ilyina; X J Ma; S Vandoninck; W H Luyten; H Vanden Bossche
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Transcriptional profiling of azole-resistant Candida parapsilosis strains.

Authors:  A P Silva; I M Miranda; A Guida; J Synnott; R Rocha; R Silva; A Amorim; C Pina-Vaz; G Butler; A G Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

6.  A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.

Authors:  Somanon Bhattacharya; Jack D Sobel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 7.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

8.  Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity.

Authors:  Rui Li; Rohitashw Kumar; Swetha Tati; Sumant Puri; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata.

Authors:  H Nakayama; N Nakayama; M Arisawa; Y Aoki
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris.

Authors:  Jizhou Li; Alix T Coste; Maroussia Liechti; Daniel Bachmann; Dominique Sanglard; Frederic Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.